OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
152159

Frontage Holdings Corp

Biotechnology & Medical ResearchVerified

Frontage Holdings Corp has a liquidity position with a current ratio of 1.33, indicating moderate short-term liquidity. The company's cash and equivalents amount to $36.3 million, while its long-term debt stands at $127.6 million, resulting in a net cash position that is negative after subtracting total debt. The debt-to-equity ratio of 0.37 suggests a relatively conservative capital structure. In terms of profitability, Frontage Holdings Corp reports a return on equity (ROE) of 1.96% and a return on assets (ROA) of 1.26%. These figures are below the industry median for ROE and ROA in the Biotechnology & Medical Research sector, indicating that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is distributed across two main geographic segments: North America and Europe, and the People's Republic of China (PRC). However, the financial data does not provide a breakdown of revenue by segment, making it difficult to assess the concentration of revenue in any particular region. Frontage Holdings Corp's revenue for the latest period is $256.7 million. While the company's outlook for the current fiscal year is not explicitly provided, the absence of analyst recommendations for a "buy" or "strong buy" suggests a neutral or cautious market sentiment. The company's growth trajectory is not clearly defined in the available data, and there is no indication of significant changes in revenue or profitability in the near term. The risk assessment for Frontage Holdings Corp indicates a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to its negative net cash position after accounting for long-term debt. There is no indication of dilution pressure in the near term, as the number of shares outstanding has not changed between basic and diluted shares. There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position.

30-day price · 1521-0.16 (-15.1%)
Low$0.86High$1.07Close$0.90As of22 May, 00:00 UTC
Profile
CompanyFrontage Holdings Corp
Ticker1521.HK
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies, including bioequivalence clinical and chemical services.

Classification. Frontage Holdings Corp is classified in the Healthcare economic sector under the Pharmaceuticals & Medical Research business sector, with a confidence level of 0.92.

Frontage Holdings Corp has a liquidity position with a current ratio of 1.33, indicating moderate short-term liquidity. The company's cash and equivalents amount to $36.3 million, while its long-term debt stands at $127.6 million, resulting in a net cash position that is negative after subtracting total debt. The debt-to-equity ratio of 0.37 suggests a relatively conservative capital structure. In terms of profitability, Frontage Holdings Corp reports a return on equity (ROE) of 1.96% and a return on assets (ROA) of 1.26%. These figures are below the industry median for ROE and ROA in the Biotechnology & Medical Research sector, indicating that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization. The company's revenue is distributed across two main geographic segments: North America and Europe, and the People's Republic of China (PRC). However, the financial data does not provide a breakdown of revenue by segment, making it difficult to assess the concentration of revenue in any particular region. Frontage Holdings Corp's revenue for the latest period is $256.7 million. While the company's outlook for the current fiscal year is not explicitly provided, the absence of analyst recommendations for a "buy" or "strong buy" suggests a neutral or cautious market sentiment. The company's growth trajectory is not clearly defined in the available data, and there is no indication of significant changes in revenue or profitability in the near term. The risk assessment for Frontage Holdings Corp indicates a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to its negative net cash position after accounting for long-term debt. There is no indication of dilution pressure in the near term, as the number of shares outstanding has not changed between basic and diluted shares. There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position.
Key takeaways
  • Frontage Holdings Corp has a conservative capital structure with a debt-to-equity ratio of 0.37.
  • The company's ROE and ROA are below the industry median, indicating underperformance in capital efficiency and asset utilization.
  • The company's liquidity position is moderate, with a current ratio of 1.33 and a negative net cash position after subtracting long-term debt.
  • There is no indication of dilution pressure in the near term, as the number of shares outstanding has not changed between basic and diluted shares.
  • The company's growth trajectory is not clearly defined in the available data, and there is no indication of significant changes in revenue or profitability in the near term.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$256.7M
Gross profit$69.2M
Operating income$18.9M
Net income$6.8M
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets$541.0M
Total liabilities$194.2M
Total equity$346.8M
Cash & equivalents$36.3M
Long-term debt$127.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$346.8M
Net cash-$91.3M
Current ratio1.3
Debt/Equity0.4
ROA1.3%
ROE2.0%
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 254 companies
Metric1521Activity
Op margin7.3%7.0% medp25 3.8% · p75 10.2%above median
Net margin2.6%2.4% medp25 -0.6% · p75 5.4%above median
Gross margin27.0%50.1% medp25 23.6% · p75 72.3%below median
CapEx / revenue-6.8% medp25 -27.8% · p75 -1.7%
Debt / equity37.0%140.5% medp25 104.0% · p75 177.0%bottom quartile
Observations
IR observations
Mean price target1.00 USD
Median price target1.00 USD
High price target1.01 USD
Low price target1.00 USD
Mean recommendation4.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count0.00
Sell count2.00
Strong-sell count0.00
Mean EPS estimate0.01 USD
Last actual EPS0.01 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 18:10 UTC#ad6559d8
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 18:12 UTCJob: 11eb960c